Mobius Therapeutics™, LLC, is a valued OOSS Marketing Partner. Marketing Partners provide products and services of interest to OOSS members. These partners support OOSS with their financial contributions. Learn more about the OOSS Partner program.
Introducing Mitosol®, the FDA approved ophthalmic formulation of Mitomycin-C, by Mobius Therapeutics™.
With the Mitosol® system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery, ophthalmic surgeons have a superior surgical solution that is:
- COMPLIANT. FDA-approved Mitosol® replaces compounding in compliance with guidance from the American Society of Health System Pharmacists.
- CONSISTENT. The Mitosol® Kit for Ophthalmic Use is reconstituted on the sterile field before use to reduce risk of drug degradation for consistent quality.
- CONTAINED. The Mitosol® closed delivery system protects operating room personnel and patients by containing hazardous mitomycin vapors.
- COST EFFECTIVE. Unlike compounded ophthalmic mitomycin, the cost of Mitosol® Kits is a CMS-approved reimbursable expense.